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A 40-year-old man who had complained of bloody spu-tum was referred to our hospital for workup. Chest
computed tomography showed a significant mediastinal
lymphadenopathy (Figure 1A). Bronchoscopic examina-
tion revealed a tumor compressing the right mainstem
bronchus (Figure 2A). Massive bleeding from the tumor
was caused by passage of the bronchoscope. Therefore, a
diagnosis of pulmonary adenocarcinoma was made by
sputum cytology. The patient first received conventional
chemotherapy in the form of four courses of cisplatin plus
vinorelbine (CDDP  VNR), two cycles of cisplatin plus gem-
citabine (CDDP  GEM), and four cycles of carboplatin plus
gemcitabine (CBDCA  GEM). However, both the size of the
tumor and the serum carcinoembryonic antigen level continued
to increase. Fluorodeoxyglucose positron emission tomography
suggested systemic metastasis in hilar and mediastinal lymph
nodes and bone (Figure 1B).
We performed endobronchial ultrasound-guided
transbronchial needle aspiration (EBUS-TBNA) to avoid
bleeding from the tumor. Metastatic adenocarcinoma was
revealed in an upper paratracheal lymph node (#2R) (Fig-
ures 2B, C). Because the epidermal growth factor receptor
gene was wild type, we examined the presence of ALK
fusion genes. Immunohistochemistry by the intercalated
antibody-enhanced polymer (iAEP) method1 showed an
expression of ALK protein in the samples obtained by
EBUS-TBNA (Figure 2D). EML4-ALK fusion gene was
also confirmed by both fluorescence in situ hybridization
(Figure 2E) and reverse transcriptase-polymerase chain
reaction (Figure 2F). Direct sequencing of the PCR prod-
uct revealed the presence of EML4-ALK variant 1. Thus,
we referred the patient for enrollment in a clinical trial
with crizotinib (PF-02341066).2 Six weeks after adminis-
tration of the crizotinib (250 mg twice a day, oral admin-
istration), the bloody sputum disappeared, and the tumor
size decreased on chest computed tomography (Figure
1C). The carcinoembryonic antigen level also normalized.
Five months after administration, an abnormal accumula-
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FIGURE 1. A, Chest computed tomography showed a nar-
rowing of the right main bronchus due to massive lymphad-
enopathy. B, FDG-PET suggested multiple lymph node me-
tastases and bone metastases. C, Six weeks after
administration of the ALK inhibitor, the effect of the treat-
ment was judged as partial response based on RECIST. D,
Five months after administration of the ALK inhibitor, abnor-
mal accumulation on FDG-PET had disappeared. FDG-PET,
fluorodeoxyglucose positron emission tomography.
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tion almost disappeared on fluorodeoxyglucose positron
emission tomography scan (Figure 1D). The observed side
effects were only slight nausea during the early period of
administration. The patient remains in good condition
without tumor relapse for 10 months. The patient suddenly
complained bilateral lower extremities paralysis, and the
spinal cord metastasis was revealed. The patient was
discontinued treatment during the trial in April 2010 be-
cause of disease progression.
DISCUSSION
Fusion of ALK with EML4 gives rise to a highly potent
oncogene in non-small cell lung cancer,3 being detected in5%
of all non-small cell lung cancer cases.1,3,4 Presence of the ALK
fusions can be detected by immunohistochemical screening4 and
can be also confirmed by fluorescence in situ hybridization and
reverse transcriptase-polymerase chain reaction.4 Recently, with
progress in chemotherapeutic research, molecular targeted ther-
apeutic agents have been developed, including ALK kinase
inhibitors that are now being clinically tested.2 Ideally, ALK
fusion gene assessment should be performed using minimally
invasive means to obtain biopsy samples sufficient for genetic
analysis for subsequent targeted molecular therapy. Histologic
as well as cytologic samples can be obtained by EBUS-TBNA,
and we have previously reported that high-quality cores are
adequate for molecular analyses for biomarkers.5 The dramatic
FIGURE 2. A, Bronchoscopic exami-
nation showed tumor compression of
the right main bronchus, and the tu-
mor had hyperplastic vessels on its
surface. B, EBUS-TBNA was performed
for a pretracheal lymph node (#2R).
C, Histologic core revealed metastatic
adenocarcinoma in #2R node. D, Im-
munohistochemistry was positive for
ALK protein using the iAEP method.
E, FISH revealed the EML4-ALK fusion
gene. EML4-ALK split assay with la-
beled probes for the upstream (red)
and downstream (green, arrow) re-
gion of the ALK locus. EML4-ALK fu-
sion assay with labeled probes for
EML4 (green, arrow) or ALK (red, ar-
row). Fusion gene showed EML4-ALK
(arrow). F, RT-PCR using specific
primer set for each variant also con-
firmed the presence of EML4-ALK
variant 1 (274bp). The presence of
variant 1 type fusion was also con-
firmed by direct sequence of the RT-
PCR product (data not shown). RT-
PCR, reverse transcriptase-polymerase
chain reaction; FISH, fluorescence in
situ hybridization.
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effect of the ALK inhibitor in this patient demonstrates that
adequate biomarker assessment contributes to the optimum se-
lection of reagents in targeted molecular therapy and in individ-
ualized treatment.
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